title: Synergistic antitumor effect of JAWSII dendritic cells and interleukin             12 in a melanoma mouse model.
abstract: One of the possible ways to augment dendritic cell (DC) efficacy in presentation             of tumor antigens to effector T cells is pulsing them with tumor-cell lysates             and incubation with certain immunostimulators. We present the results of an immunotherapeutic             approach in a murine B78-H1 model using as a vaccine JAWSII DCs in combination             with IL-12. Prior to the in vivo experiments, phenotypic characterization of JAWSII             cells was performed and optimal conditions for stimulation of these cells were             established. As no production of IL-12 by JAWSII cells was found, injections of             this cytokine were introduced to vaccination protocols. Three vaccination schedules             have been tested: i) prophylactic, ii) therapeutic-intratumoral, and iii) therapeutic-systemic.             In all the protocols, vaccination with pulsed + stimulated JAWSII cells in combination             with IL-12 was superior to the treatment with either agent alone and led to eradication             of the tumor in several cases. The results of the study may be helpful in planning             optimal DC-based therapeutic protocols in cancer patients.
authors.affiliation: Department of Immunology, Centre of Biostructure Research, Medical                     University of Warsaw, 02-097 Warsaw, Poland.
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Zapała
authors.forename: Rafał
authors.initials: R
authors.lastname: Wolny
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Wachowska
authors.forename: Marek
authors.initials: M
authors.lastname: Jakóbisiak
authors.forename: Witold
authors.initials: W
authors.lastname: Lasek
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D019496:Cancer Vaccines; D002457:Cell Extracts / Q000276:immunology; D002460:Cell Line; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000502:physiology; D007167:Immunotherapy; D007371:Interferon-gamma / Q000494:pharmacology / Q000502:physiology; D018664:Interleukin-12 / Q000008:administration & dosage* / Q000502:physiology; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010587:Phagocytosis; D011070:Poly I-C / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D019496:Cancer Vaccines; D002457:Cell Extracts; D007155:Immunologic Factors; D018664:Interleukin-12; D007371:Interferon-gamma; D011070:Poly I-C